Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29347)	10/29/1999 3:19:00 AM
From: Cheryl Galt	Read Replies (3) \| Respond to of 32384

Thanks, Bob for SERM-beta information. Please post any other SERM candidates you hear about. I've been trying to track the SERMs and anti-estrogens, and their varying properties. But I'm finding it nearly impossible to collect this information. Drugs being developed by big pharmas and privately held biotechs have little visibility to us. And I've found no systematic, time-efficient way to find those that are visible. Any ideas, anyone ??? ------------------------- Quite a few anti-estrogens are being tested in relation to Tamoxifen 1) head to head vs TMX, as 5-year adjuvant therapy after BC surgery 2) head to head vs TMX, after BC recurs 3) after BC recurs and TMX has failed Third generation Anti-estrogens called Aromatase Inhibitors (AIs) have been showing good results in Category 3 -- after tamoxifen fails. And they are gaining ground in Category 2. Sooooo, in advanced breast cancer after Tamoxifen fails, there actually IS hope -- currently, approved and on the market. (I want to find the $Sales figures for the AIs.) I'm surprised I've seen no discussion of AIs on SI. AIs include AZN's anastrozole and PNU's exemestane (which was just recently in the news). These two are opposite types of AI (steroidal and non-steroidal), and might even synergize with each other. Many clinical tests are ongoing. ----------- A question for anyone ... For treatment of ABC after tamoxifen fails, are the AIs in competition with Targretin? or likely to synergize with it? I would guess they would synergize ...